Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 8, 2011, Pages 3342-3347

  Cima, Igor ^a   Schiess, Ralph ^a   Wild, Peter ^b   Kaelin, Martin ^c   Schüffler, Peter ^a   Lange, Vinzenz ^a   Picotti, Paola ^a   Ossola, Reto ^a   Templeton, Arnoud ^c   Schubert, Olga ^a   Fuchs, Thomas ^a   Leippold, Thomas ^d   Wyler, Stephen ^d   Zehetner, Jens ^a   Jochum, Wolfram ^e   Buhmann, Joachim ^a   Cerny, Thomas ^c   Moch, Holger ^b   Gillessen, Silke ^c   Aebersold, Ruedi ^a,f   Krek, Wilhelm ^a   more..

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Kantonsspital St Gallen ^*  (Switzerland)

^d Kantonsspital St Gallen Klinik fur Urologie   (Switzerland)

^e Institute of Pathology   (Switzerland)

^f UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Mass spectrometry; Pten conditional knockout mouse model; Serum biomarkers

Indexed keywords

BIOLOGICAL MARKER; GLYCOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR MARKER;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BIOINFORMATICS; CANCER DIAGNOSIS; CANCER GENETICS; CELL DIFFERENTIATION; CONTROLLED STUDY; FOURIER TRANSFORMATION; GENE INACTIVATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; SERUM; STEM CELL; TUMOR SUPPRESSOR GENE;

ANIMALS; COMPUTATIONAL BIOLOGY; GENE SILENCING; GLYCOPROTEINS; HUMANS; MALE; METHODS; MICE; PROSTATIC NEOPLASMS; PROTEOMICS; PTEN PHOSPHOHYDROLASE; TUMOR MARKERS, BIOLOGICAL;

MURINAE; MUS;

EID: 79952751238     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1013699108     Document Type: Article

References (42)

1. Tainsky MA (2009) Genomic and proteomic biomarkers for cancer: A multitude of opportunities. Biochim Biophys Acta 1796:176-193.
2. Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5:845-856.
3. Srinivas PR, Kramer BS, Srivastava S (2001) Trends in biomarker research for cancer detection. Lancet Oncol 2:698-704.
4. Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat Biotechnol 24:971-983.
5. Steck PA, et al. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362.
6. Maehama T, Dixon JE (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378.
7. Stambolic V, et al. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:29-39.
8. Mehrian-Shai R, et al. (2007) Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA 104:5563-5568.
9. Trotman LC, et al. (2003) Pten dose dictates cancer progression in the prostate. PLoS Biol 1:E59.
10. Zhang H, et al. (2007) Mass spectrometric detection of tissue proteins in plasma. Mol Cell Proteomics 6:64-71.
11. Schiess R, Wollscheid B, Aebersold R (2009) Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol 3(1):33-44.
12. Zhang H, Li XJ, Martin DB, Aebersold R (2003) Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 21:660-666.
13. Emanuelsson O, Brunak S, von Heijne G, Nielsen H (2007) Locating proteins in the cell using TargetP, SignalP and related tools. Nat Protoc 2:953-971.
14. Roth J (2002) Protein N-glycosylation along the secretory pathway: Relationship to organelle topography and function, protein quality control, and cell interactions. Chem Rev 102:285-303.
15. Mueller LN, et al. (2007) SuperHirn - a novel tool for high resolution LC-MS-based peptide/protein profiling. Proteomics 7:3470-3480.
16. Liu H, Sadygov RG, Yates JR, 3rd (2004) A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 76:4193-4201.
17. Wang S, et al. (2006) Pten deletion leads to the expansion of a prostatic stem/ progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci USA 103: 1480-1485.
18. Saal LH, et al. (2007) Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 104:7564-7569.
19. Sircar K, et al. (2009) PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 218: 505-513.
20. Yoshimoto M, et al. (2006) Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 169:128-137.
21. Addona T, et al. (2009) Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 27(7):633-641.
22. Lange V, Picotti P, Domon B, Aebersold R (2008) Selected reaction monitoring for quantitative proteomics: A tutorial. Mol Syst Biol 4:222.
23. Breiman L (2001) Random forests. Mach Learn 45:5-32.
24. Efron B, Tibshirani R (1993) An Introduction to the Bootstrap (Chapman & Hall, New York).
25. McMenamin ME, et al. (1999) Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59:4291-4296.
26. Dreher T, et al. (2004) Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch 444:509-517.
27. Nakanishi H, et al. (2008) PCA3 molecular urine assay correlates with prostate cancer tumor volume: Implication in selecting candidates for active surveillance. J Urol 179 (5):1804-1809; discussion 1809-1810.
28. Sreekumar A, et al. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457:910-914.
29. Bastian PJ, et al. (2009) Insignificant prostate cancer and active surveillance: From definition to clinical implications. Eur Urol 55:1321-1330.
30. Schröder FH, et al.; ERSPC Investigators (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328.
31. Andriole GL, et al.; PLCO Project Team (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-1319.
32. Zhang J, et al. (2002) Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development. Gene 283:83-93.
33. Ransohoff DF (2005) Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 5:142-149.
34. Neal DE, Donovan JL, Martin RM, Hamdy FC (2009) Screening for prostate cancer remains controversial. Lancet 374:1482-1483.
35. Engelman JA (2009) Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer 9:550-562.
36. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627-644.
37. Sarker D, Reid AH, Yap TA, de Bono JS (2009) Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 15:4799-4805.
38. Pedrioli PGA, et al. (2004) A common open representation of mass spectrometry data and its application to proteomics research. Nat Biotechnol 22:1459-1466.
39. Schiess R, et al. (2009) Analysis of cell surface proteome changes via label-free, quantitative mass spectrometry. Mol Cell Proteomics 8(4):624-638.
40. Su AI, et al. (2002) Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci USA 99:4465-4470.
41. Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP (2003) Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci USA 100:6940-6945.
42. Kononen J, et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847.